Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial

• Published in: Vaccine Vol. 42; no. 3; pp. 662 - 670
• Main Authors: Kuriyama, Kenji, Murakami, Kyoko, Sugiura, Kenkichi, Sakui, Sho, Schuring, Ron P., Mori, Mitsuhiro
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 25.01.2024; Elsevier Limited
• Subjects: Adult; Adults; Adverse events; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Heterologous booster; Humans; IgG antibody; Immune response; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Infections; Japan; Labels; mRNA; mRNA Vaccines; NVX-CoV2373; Robustness; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccine immunogenicity; Vaccine safety; Vaccines; Japan; United Kingdom > UK; United States > US; LLOQ; rS; SAP; SCR; AE; AESI; CoP; CI; IgG; Vaccine safety; EU/mL; Heterologous booster; nAb; GMT; COVID-19; SARS-CoV-2; GMFR; SAE; MN50; Vaccine immunogenicity; MAAE; NVX-CoV2373; ULOQ; ELISA

•This study assessed two NVX-CoV2373 boosters given 5 months apart in Japanese adults.•This is the first assessment of a second NVX-CoV2373 booster in Japanese adults.•The second booster induced more robust immune responses than the first booster.•Neutralizing antibody titres were 1.4-fold higher th...